NCT03776058View on ClinicalTrials.gov

Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 15, 2000

Primary Completion Date

December 26, 2000

Study Completion Date

December 26, 2000

Conditions
Primary Hyperparathyroidism
Interventions
DRUG

Cinacalcet

Tablets for oral administration

DRUG

Placebo

Tablets for oral administration

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03776058 - Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT) | Biotech Hunter | Biotech Hunter